| Trametinib studied in …STUDIED_INderived200 of 224show all (up to 200) |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04111458Phase 1 · active not recruiting A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02015117Phase 1 · active not recruiting Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases · 224 trials list this drug (69 active) | — | — | Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06475989Phase 3 · recruiting Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07468071Phase 1/Phase 2 · recruiting Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03340506Phase 4 · recruiting Dabrafenib and/or Trametinib Rollover Study · 224 trials list this drug (69 active) | — | — | Solid Neoplasm,Melanoma,Lung Non-Small Cell Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03899155Phase 2 · recruiting Pan Tumor Rollover Study · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04940052Phase 3 · active not recruiting Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544111Phase 2 · active not recruiting PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Follicular Carcinoma,Malignant Thyroid Gland Neoplasm,Thyroid Gland Oncocytic Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02196181Phase 2 · active not recruiting Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread · 224 trials list this drug (69 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03149029Phase 2 · active not recruiting Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02079740Phase 1/Phase 2 · active not recruiting Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors · 224 trials list this drug (69 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04201457Phase 1/Phase 2 · active not recruiting A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02642042Phase 2 · active not recruiting Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05849662Phase 1/Phase 2 · recruiting A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia · 224 trials list this drug (69 active) | — | — | Juvenile Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07110246Phase 2 · recruiting Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas · 224 trials list this drug (69 active) | — | — | Low Grade Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04557956Phase 1/Phase 2 · active not recruiting Testing the Addition of the Anti-cancer Drug, Tazemetostat, to (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02152995Phase 2 · active not recruiting Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Follicular Carcinoma,Thyroid Gland Carcinoma,Thyroid Gland Papillary Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02224781Phase 3 · active not recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975829Phase 4 · active not recruiting Pediatric Long-Term Follow-up and Rollover Study · 224 trials list this drug (69 active) | — | — | Anaplastic Astrocytoma,Anaplastic Ganglioglioma,Anaplastic Oligodendroglioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02858921Phase 2 · active not recruiting Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05180825Phase 2 · recruiting Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy · 224 trials list this drug (69 active) | — | — | Pleomorphic Xanthoastrocytoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04485559Phase 1 · recruiting Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) · 224 trials list this drug (69 active) | — | — | Glioma,Low Grade Glioma,High-Grade Glioma, NOS | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07440290Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. · 224 trials list this drug (69 active) | — | — | Neoplasm by Site,Malignant Neoplasm,Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01989585Phase 1/Phase 2 · active not recruiting Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma · 224 trials list this drug (69 active) | — | — | Malignant Solid Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04675710Phase 2 · active not recruiting Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Anaplastic Carcinoma,Thyroid Gland Anaplastic Carcinoma, Squamous Cell Carcinoma Pattern | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02231775Phase 2 · active not recruiting Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation · 224 trials list this drug (69 active) | — | — | Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07131059NA · recruiting MRD-positive AML Clinical Study · 224 trials list this drug (69 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01979523Phase 2 · active not recruiting Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma · 224 trials list this drug (69 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04527549Phase 2 · terminated Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02101788Phase 2/Phase 3 · completed Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer · 224 trials list this drug (69 active) | — | — | Borderline Ovarian Serous Tumor,Micropapillary Serous Carcinoma,Ovarian Serous Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03091257Phase 1 · active not recruiting A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma · 224 trials list this drug (69 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03065387Phase 1 · terminated Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation · 224 trials list this drug (69 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03190915Phase 2 · active not recruiting Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia · 224 trials list this drug (69 active) | — | — | Juvenile Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439318Phase 2 · active not recruiting Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439357Phase 2 · active not recruiting Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2) · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03087071Phase 2 · active not recruiting Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer · 224 trials list this drug (69 active) | — | — | Colorectal Adenocarcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03225664Phase 1/Phase 2 · active not recruiting Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-small Cell Lung Cancer That Is Metastatic, Unresectable, or Locally Advanced · 224 trials list this drug (69 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03919071Phase 2 · active not recruiting Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma · 224 trials list this drug (69 active) | — | — | Anaplastic Astrocytoma,Anaplastic Ganglioglioma,Anaplastic Pleomorphic Xanthoastrocytoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04116541Phase 2 · recruiting A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. · 224 trials list this drug (69 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03085056early Phase 1 · active not recruiting Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04238624Phase 2 · active not recruiting Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Neoplasm,Malignant Thyroid Gland Neoplasm,Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01972347Phase 2 · completed Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05358249Phase 1/Phase 2 · active not recruiting Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation · 224 trials list this drug (69 active) | — | — | Colorectal Neoplasm,Lung Non-Small Cell Carcinoma,Colorectal Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439292Phase 2 · active not recruiting Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H) · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02910700Phase 2 · active not recruiting Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03825289Phase 1 · terminated Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer · 224 trials list this drug (69 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04439279Phase 2 · active not recruiting Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R) · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03784014Phase 3 · completed Molecular Profiling of Advanced Soft-tissue Sarcomas · 224 trials list this drug (69 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03363217Phase 2 · active not recruiting Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway. · 224 trials list this drug (69 active) | — | — | Low Grade Glioma,Plexiform Neurofibroma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01682083Phase 3 · completed Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05518110Phase 2 · terminated PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer · 224 trials list this drug (69 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975231Phase 1 · recruiting Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04892017Phase 1 · terminated Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors · 224 trials list this drug (69 active) | — | — | Solid Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03244956Phase 2 · completed Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06804824Phase 1 · recruiting A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07477457Phase 2 · recruiting A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma · 224 trials list this drug (69 active) | — | — | Osteosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04417621Phase 2 · active not recruiting Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03501368Phase 1 · completed Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05907304Phase 1 · active not recruiting A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06346067Phase 3 · active not recruiting A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04666272active not recruiting Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04903119Phase 1 · recruiting Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03333343Phase 1 · active not recruiting Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04452877Phase 2 · completed A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04294160Phase 1 · terminated A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04489433no longer available Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04961619completed Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03377361Phase 1/Phase 2 · completed An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread · 224 trials list this drug (69 active) | — | — | Colorectal Neoplasm,Colorectal Carcinoma,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05668585Phase 1 · completed A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors · 224 trials list this drug (69 active) | — | — | Solid Neoplasm,Melanoma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04185883Phase 1 · active not recruiting Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02967692Phase 3 · terminated A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05658640Phase 1/Phase 2 · recruiting HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies · 224 trials list this drug (69 active) | — | — | Acute Lymphoblastic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05372354Phase 1/Phase 2 · recruiting A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma · 224 trials list this drug (69 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01723202Phase 2 · completed Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Follicular Carcinoma,Thyroid Gland Neoplasm,Malignant Thyroid Gland Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01990196Phase 2 · active not recruiting Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer · 224 trials list this drug (69 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02230553Phase 1/Phase 2 · completed Lapatinib Plus Trametinib in KRAS Mutant NSCLC · 224 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07010393Phase 4 · not yet recruiting Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study · 224 trials list this drug (69 active) | — | — | Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05440942Phase 1 · completed Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma · 224 trials list this drug (69 active) | — | — | Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03299088Phase 1 · completed Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704688Phase 1/Phase 2 · completed Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06962254Phase 1 · recruiting Imatinib and Trametinib for KRAS-mutated Solid Tumor · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03551626Phase 3 · completed Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04487106Phase 2 · completed Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome · 224 trials list this drug (69 active) | — | — | Myelodysplastic Syndrome,Acute Myeloid Leukemia,Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02974725Phase 1 · terminated A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05275374Phase 1/Phase 2 · not yet recruiting XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm,Melanoma,Lung Non-Small Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06119789Phase 2 · recruiting Precision Cancer Therapy in Rare Cancers · 224 trials list this drug (69 active) | — | — | Rare Childhood Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05260684completed Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02070549Phase 1 · completed Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction · 224 trials list this drug (69 active) | — | — | Solid Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026517Phase 1 · completed Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01902173Phase 1/Phase 2 · completed Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm,Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06739395Phase 2 · recruiting Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03148275Phase 2 · completed Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery · 224 trials list this drug (69 active) | — | — | Epithelioid Hemangioendothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04544202no longer available Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04310397Phase 2 · terminated Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06653517Phase 2 · recruiting Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma · 224 trials list this drug (69 active) | — | — | Ameloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02097225Phase 1 · terminated Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · 224 trials list this drug (69 active) | — | — | Solid Neoplasm,Malignant Solid Neoplasm,Melanoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532149recruiting ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03631953Phase 1 · unknown Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas · 224 trials list this drug (69 active) | — | — | Meningioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03455764Phase 1/Phase 2 · completed MCS110 With BRAF/MEK Inhibition in Patients With Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159245Phase 2 · recruiting The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06456138Phase 1/Phase 2 · not yet recruiting Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC · 224 trials list this drug (69 active) | — | — | Neoplasm,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05435846Phase 1 · terminated Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation · 224 trials list this drug (69 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03434262Phase 1 · completed SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors · 224 trials list this drug (69 active) | — | — | Neoplasm,Embryonal Neoplasm,Central Nervous System Embryonal Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04967079Phase 1 · completed Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03741101Phase 2 · unknown Treatment of NF1-related Plexiform Neurofibroma With Trametinib · 224 trials list this drug (69 active) | — | — | Plexiform Neurofibroma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03317119Phase 1 · completed Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery · 224 trials list this drug (69 active) | — | — | Colorectal Carcinoma,Malignant Colorectal Neoplasm,Colon Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03076164Phase 1/Phase 2 · completed A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib · 224 trials list this drug (69 active) | — | — | Lung Neoplasm,Malignant Lung Neoplasm,Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05071183Phase 1/Phase 2 · terminated A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid Tumors · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739566Phase 2 · withdrawn Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer · 224 trials list this drug (69 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 224 trials list this drug (69 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03516214Phase 1 · completed EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02367859Phase 2 · completed Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma · 224 trials list this drug (69 active) | — | — | Ameloblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 224 trials list this drug (69 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02684058Phase 2 · completed Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors · 224 trials list this drug (69 active) | — | — | Anaplastic Astrocytoma,Anaplastic Ganglioglioma,Anaplastic Oligodendroglioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05876806Phase 2 · unknown Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02143050Phase 1/Phase 2 · withdrawn Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05182931Phase 2 · unknown A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) · 224 trials list this drug (69 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04303403Phase 1 · unknown Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma · 224 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01827384Phase 2 · completed MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations · 224 trials list this drug (69 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04059224Phase 2 · completed TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03272464Phase 1 · terminated INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01740648Phase 1 · completed Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer · 224 trials list this drug (69 active) | — | — | Malignant Rectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05299580Phase 2 · withdrawn "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)" · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03714958Phase 1 · completed Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02034110Phase 2 · completed Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04566133Phase 2 · terminated Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC). · 224 trials list this drug (69 active) | — | — | Malignant Bile Duct Neoplasm,Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05677373Phase 1/Phase 2 · withdrawn Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma · 224 trials list this drug (69 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03563729Phase 2 · recruiting Melanoma Metastasized to the Brain and Steroids · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04619316Phase 2 · unknown Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition · 224 trials list this drug (69 active) | — | — | Malignant Thyroid Gland Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03428126Phase 2 · completed Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer · 224 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm,Malignant Colon Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04801966NA · terminated Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01912625Phase 1 · terminated Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02881242Phase 2 · active not recruiting Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer · 224 trials list this drug (69 active) | — | — | Malignant Prostate Neoplasm,Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03087448Phase 1 · terminated Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02428270Phase 2 · completed A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer · 224 trials list this drug (69 active) | — | — | Adenocarcinoma,Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02130466Phase 1/Phase 2 · completed A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) · 224 trials list this drug (69 active) | — | — | Solid Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03668431Phase 2 · unknown Dabrafenib + Trametinib + PDR001 In Colorectal Cancer · 224 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05171374unknown pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02399943Phase 2 · completed A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer · 224 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01336634Phase 2 · completed Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02900664Phase 1 · completed A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib) · 224 trials list this drug (69 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01940809Phase 1 · terminated Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery · 224 trials list this drug (69 active) | — | — | Melanoma,Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01989598Phase 2 · completed Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma · 224 trials list this drug (69 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02705963Phase 1 · completed A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02083354Phase 2 · completed Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02257424Phase 1/Phase 2 · completed Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01750918Phase 1/Phase 2 · completed BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02974803Phase 2 · terminated Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases · 224 trials list this drug (69 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02124772Phase 1/Phase 2 · completed Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02292173Phase 1 · completed Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer · 224 trials list this drug (69 active) | — | — | Hepatocellular Carcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02296112Phase 2 · completed Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03754179Phase 1/Phase 2 · unknown Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02110355Phase 1 · completed A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma · 224 trials list this drug (69 active) | — | — | Neoplasm,Malignant Neoplasm,Solid Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01597908Phase 3 · completed Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01584648Phase 3 · completed A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02703571Phase 1 · terminated Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01155453Phase 1 · completed A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03352947Phase 2 · completed Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03972046Phase 2 · withdrawn Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01935973Phase 1 · completed Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer · 224 trials list this drug (69 active) | — | — | Endometrial Adenocarcinoma,Endometrial Serous Adenocarcinoma,Endometrial Undifferentiated Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02410863Phase 2 · terminated Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03088176Phase 1 · unknown Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01467310early Phase 1 · completed Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 · 224 trials list this drug (69 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01941927Phase 2 · completed Trametinib With GSK2141795 in BRAF Wild-type Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03232892Phase 2 · terminated Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02439411completed Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01964924Phase 2 · completed Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer · 224 trials list this drug (69 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma,Invasive Breast Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01938443Phase 1 · completed A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors · 224 trials list this drug (69 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01072175Phase 2 · completed Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01958112Phase 2 · terminated GSK1120212+GSK2141795 for Cervical Cancer · 224 trials list this drug (69 active) | — | — | Malignant Cervical Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02300935Phase 1 · withdrawn Study of Trametinib and Nab-paclitaxel in Patients With Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02039947Phase 2 · completed Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02027961Phase 1 · completed Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231594Phase 1 · completed A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02016729Phase 1 · completed A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm,Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01376310Phase 2 · terminated GSK1120212 Rollover Study · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02314143Phase 2 · terminated Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02258607Phase 1 · terminated Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma with KRAS Mutation | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03386071no longer available Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02580708Phase 1/Phase 2 · terminated Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02447939Phase 1 · withdrawn Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02939846Phase 1 · withdrawn Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01438554Phase 1 · completed Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma · 224 trials list this drug (69 active) | — | — | Solid Neoplasm,Soft Tissue Sarcoma,Malignant Thyroid Gland Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01978236Phase 2 · terminated Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites · 224 trials list this drug (69 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02672358Phase 2 · withdrawn Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC · 224 trials list this drug (69 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02065063Phase 1 · completed A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02915666Phase 1 · withdrawn A Clinical Trial of Patients With Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01907815Phase 2 · terminated Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia · 224 trials list this drug (69 active) | — | — | Adult Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01245062Phase 3 · completed GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01721603Phase 2 · terminated Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets · 224 trials list this drug (69 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01328106Phase 2 · withdrawn Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm,Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03266159Phase 2 · withdrawn A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01767454Phase 1 · completed Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00687622Phase 1 · completed Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01138085Phase 1 · completed Safety, Pharmacokinetics (PK) of AKT and MEK Combination · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01192165Phase 1 · completed Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01324258Phase 1 · completed Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors · 224 trials list this drug (69 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371487Phase 1 · completed GSK1120212 Food-effect Study · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01387204Phase 1 · completed Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212 · 224 trials list this drug (69 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |